AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Alnylam Pharmaceuticals I... (ALNY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

250.49

-5.96 (-2.32%)

At close: Feb 18, 2025, 3:59 PM

250.00

-0.20%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	248.48
Market Cap	32.43B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.18
PE Ratio (ttm)	-114.9
Forward PE	n/a
Analyst	Buy

Ask	261.46
Volume	633,281
Avg. Volume (20D)	660,379
Open	256.95
Previous Close	256.45
Day's Range	249.16 - 259.95
52-Week Range	141.98 - 304.39
Beta	undefined

About ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2004

Employees 2,230

Stock Exchange NASDAQ

Ticker Symbol ALNY

Website https://www.alnylam.com

Full Company Profile

Analyst Forecast

According to 23 analyst ratings, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $300, which is an increase of 19.77% from the latest price.

Buy 78.26%

Hold 17.39%

Sell 4.35%

Stock Forecasts

Next Earnings Release

Alnylam Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+8.53%

Alnylam Pharmaceuticals shares are trading higher.... Unlock content with Pro Subscription

3 months ago

-3.88%

Alnylam Pharmaceuticals shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform.

News

4 days ago · zacks.com

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.

6 days ago · seekingalpha.com

Alnylam: Waiting For Regulatory Updates In March

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchi...

6 days ago · fool.com

Alnylam Delivers a Big Q4 Earnings Beat

Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) ca...

5 days ago · seekingalpha.com

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO ...

5 days ago · zacks.com

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Stre...

5 days ago · zacks.com

Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a year a...

1 week ago · zacks.com

ILMN vs. ALNY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value inves...

1 week ago · zacks.com

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

1 week ago · zacks.com

Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter...

1 week ago · zacks.com

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News